Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

JAMA Study Demonstrates Efficacy of Life Technologies' Lung Cancer Test

Published: Thursday, November 08, 2012
Last Updated: Thursday, November 08, 2012
Bookmark and Share
Genetic test identifies patients at high risk for mortality in the earliest stage of lung cancer. Study suggests test could maximize the benefits of early screening if used in combination with computed tomography.

Life Technologies Corporation announced publication in the Journal of the American Medical Association1 (JAMA) of a study that underscores the clinical utility of the company's early stage lung cancer test, Pervenio™ Lung RS. Launched in September 2012, the genetic test has now been demonstrated to reliably identify patients who are at high risk for mortality following surgery even for the earliest stage of lung cancer.

The test was initially validated through two independent, blinded retrospective studies involving approximately 1,500 patients, which were published in the March 2012 issue of The Lancet.2 The new study reports data from a subset of patients included in the larger validation studies. Specifically, it looks at those patients with "T1a, node-negative" tumors, cancers that are smaller than two centimeters in diameter and that have no detectable spread of the disease.

"We know that roughly a quarter of patients with T1a, node negative tumors will die within five years, most often with recurrent lung cancer," said Michael Mann, M.D., senior author of the study. "And yet these patients do not receive any chemotherapy following surgery because there are no guidelines for identifying which T1a patients are at high risk for mortality."

Dr. Mann is associate professor of cardiothoracic surgery at the University of California, San Francisco and was involved in the development of the PervenioTM Lung RS test along with co-author David Jablons, M.D., chief of general thoracic surgery at the University of California, San Francisco.

"By the time the disease recurrence can be detected, it is too late for therapies to be curative," said Dr. Jablons. "We know from previous clinical trials that chemotherapy can cure metastatic lung cancer when it is treated even before it can be detected. Therefore, we need to identify the high-risk patients earlier, immediately after surgery if possible. Current published guidelines already recommend consideration of chemotherapy at that time even for stage I patients who are believed to be at the highest risk."

Pervenio™ Lung RS is a genetic test that examines activity of 14 genes in tumor tissue. The current JAMA study demonstrates that the test accurately predicted mortality risk among 269 T1a, node-negative patients. The test categorized 92 patients as high risk; survival among these patients was just over 50 percent. In contrast, survival among patients classified by the test as low risk was nearly 85 percent.  Further, when patients with tumors smaller than one centimeter were examined, 100 percent of the low-risk patients survived, as compared to just over 30 percent of the patients determined to be at high risk by the test.

"Physicians don't need to send these early stage patients home for 'watchful waiting' anymore, knowing that a good percentage of them will see their cancer recur and many of those will die," said Ronnie Andrews, president of Medical Sciences at Life Technologies. "We haven't seen survival rates for early stage lung cancer improve significantly during the past 30 years, but now we have a tool that can help enable more patients to receive a treatment that may increase their survival closer to what we see in diseases in which we have made progress, such as breast and colon cancer."

Five-year survival rates for stage I lung cancer are approximately 60 percent. By comparison, patients with stage I colon or breast cancer can expect surgical cure rates of greater than 90 percent. In addition, genetic testing of tumors may play a role in extending early screening efforts.

"Currently, the issue of screening for lung cancer is somewhat controversial," said Dr. Mann. "One challenge of screening is how to maximize the chances of survival for a dramatically increased number of patients who would be diagnosed at the very earliest stages. Right now, a quarter or more of those patients would still die, despite early detection. The Pervenio™ test could add a layer of sophistication and personalization to the care of that growing population that could improve survival rates even further."

"There is also a movement toward limiting the loss of healthy lung tissue to lung cancer operations," Dr. Jablons added, "but there is concern that important prognostic information currently used in conventional staging might be lost with less radical surgery. Pervenio™ has been shown to provide even more accurate information about prognosis and would therefore enable equal or even better clinical management decisions with lung-sparing operations."

Pervenio™ Lung RS is available through the Life Technologies' Clinical Services Lab, which is licensed in all 50 U.S. states. Life Technologies also plans to make Pervenio™ Lung RS available outside of the United States, so the test can be broadly deployed on Life Technologies' regulated platforms, including the 7500 Fast Dx for qPCR.

The study, titled "Ability of a Prognostic Assay to Identify Patients at High Risk of Mortality Despite Small, Node-Negative Lung Tumors," was supported by private endowments to the UCSF Thoracic Oncology Laboratory and by Pinpoint Genomics, which Life Technologies acquired in July 2012.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FBI Approves Life Technologies' Forensics Kit
Ability to upload forensic samples to National DNA Index System using GlobalFiler DNA chemistry enables faster, more powerful data comparisons to solve crimes in the U.S. and globally.
Tuesday, June 24, 2014
Life Tech's Food Pathogen Detection Methods Approved by Australian Government
MicroSEQ Real-Time PCR workflows approved as method for testing Australian export meat and meat products.
Tuesday, December 17, 2013
Life Technologies Awards Digital PCR Innovation Grants to Five Research Labs
The five Innovation Grant recipients in the Digital PCR Applications Grant Program was announced during the ASHG conference in Boston.
Thursday, October 24, 2013
Thermo Acquisition Approved by Life Technologies Stockholders
Company announced that its stockholders voted to adopt the previously announced merger agreement.
Thursday, August 22, 2013
Life Technologies Announces Second Quarter 2013 Results
Revenue increased 1% excluding impact of currency.
Thursday, August 01, 2013
Life Technologies Signs Five-Year Agreement with the FDA
The agreement aims to accelerate and advance food safety testing of E. coli and Salmonella, two foodborne contaminants commonly associated with outbreaks and/or recalls.
Tuesday, July 30, 2013
Life Technologies Expands CEERAM Food Safety Range to Global Market
Award-winning products broaden industry-leading portfolio of food safety solutions.
Friday, July 26, 2013
Life Technologies Expands Line of qPCR Instruments
Company simultaneously introduces two flexible systems in the QuantStudio™ product line designed to meet varying throughput and budget needs of customers.
Thursday, July 25, 2013
Life Technologies to Collaborate with Merck Serono
Long-term collaboration is aimed at developing, obtaining regulatory approval and commercializing companion diagnostics for selected Merck Serono drug development programs.
Wednesday, July 17, 2013
Life Technologies Screening Technology Receives Emergency Use Authorization
Life Technologies supports global effort to help accelerate emergency screening of Novel Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Wednesday, June 26, 2013
Life Technologies Acquires Life Science Korea
The acquisition strengthens Life Tech's go-direct strategy in South Korea.
Friday, June 14, 2013
Life Technologies Begins Shipping QuantStudio™ 3D Digital PCR System
Disruptive benchtop system makes digital PCR attainable to any lab.
Tuesday, June 11, 2013
Life Technologies Supports Emergency Screening of Avian Influenza (H7N9) Virus
Company's instruments FDA-cleared under Emergency Use Authorization declaration.
Monday, April 29, 2013
Life Technologies to Invest $18 Million in Facility Expansion and Current GMP Compliance Plan
Project aims to broaden product offerings to growing diagnostics and pharmaceutical customer base.
Tuesday, April 02, 2013
Life Technologies Signs Stem Cell Agreement with Harvard University
Research collaboration aimed at yielding standardized method for evaluating iPS cell quality; deepens Life's investment to its expanding stem cell product portfolio.
Tuesday, March 05, 2013
Scientific News
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Using Cancer Cells' Mass to Predict Treatment Response
A device has been developed that can detect changes in cell mass at a minute scale.
NVIDIA Awards $400k to Trailblazers in Cancer Research
NVIDIA Foundation furthers research that could lead to new and more targeted treatments with investments.
Malaria Parasite Evades Rapid Test Detection in Children
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Working With Advanced Nanoimagers
Oxford Nanoimaging report on the work of early-adopters for their Nanoimager technology at the MRC Centre for Molecular Bacteriology and Infection.
History of Cells Told Through MEMOIR
MEMOIR technique developed by CalTech researchers enables the life history of cells to be read.
Nanoscale ‘Muscles’ Powered by DNA
Scientists have developed nanoscale "muscles" to integrate with custom DNA, that can force the material to bend, curl and flip.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Cancer Stem Cells Fuel Tumor Growth
Mass. General, Broad Institute team finds strong evidence that cancer stem cells are important drivers of tumors in patients.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!